Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its RADR(R) AI platform to transform oncology drug discovery and development, presented clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress in New York City, showing a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma after failure of four prior regimens, including CAR-T and bispecific antibody therapies. The response, achieved after two 28-day cycles of LP-284, supports the drug’s synthetic lethal mechanism and potential to fill a critical post-immunotherapy treatment gap. Lantern CEO Panna Sharma said the results validate the company’s AI-driven approach and highlight LP-284’s dual potential as a monotherapy and in combination with FDA-approved agents such as rituximab. Lantern noted LP-284’s favorable early safety profile, multiple FDA Orphan Drug Designations, strong IP protection through 2039, and partnership opportunities for expanding hematology portfolios.
To view the full press release, visit https://ibn.fm/VJkna
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit www.AINewsWire.com
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com
AINewsWire is powered by IBN
Disseminated on behalf of BTQ Technologies Corp. and may include paid advertising. BTQ (NASDAQ: BTQ)…
Nightfood Holdings (OTCQB: NGTF), doing business as TechForce Robotics, announced the acquisition of technology, designs…
ECGI Holdings (OTC: ECGI) announced its placement in an AINewsWire editorial titled "How Artificial Intelligence…
ECGI Holdings (OTC: ECGI), a publicly traded holding company focused on health care through its…
AZIO AI Holdings (NASDAQ: AZIO) has unveiled Atlas One, a South Texas data center campus…
Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid…